Despite the presence of TDP-43 pathology in the vast majority of ALS patients, no study to date have thoroughly investigated the direct effects of TARDBP mutations on systemic metabolism in patients. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.